Novartis Zelnorm sNDA For Chronic Constipation To Be Reviewed By Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
New indication for intestinal bowel syndrome drug Zelnorm will be considered by FDA’s Gastrointestinal Drugs Advisory Committee July 14. Severe diarrhea and ischemic colitis associated with Zelnorm use are likely to be discussed.
You may also be interested in...
Naltrexone IBS Studies Show Superior Risk Profile Vs. Lotronex, Zelnorm, Pain Therapeutics Says
Pain Therapeutics is conducting two Phase III studies for the opioid antagonist in men and women with chronic IBS. The next IBS agent on the market, however, is likely to be Solvay's Calmactin.
Naltrexone IBS Studies Show Superior Risk Profile Vs. Lotronex, Zelnorm, Pain Therapeutics Says
Pain Therapeutics is conducting two Phase III studies for the opioid antagonist in men and women with chronic IBS. The next IBS agent on the market, however, is likely to be Solvay's Calmactin.
Monoclonal Antibodies for Inflammatory Bowel Disease Take Center Stage At Digestive Disease Week
Studies of Biogen Idec/Elan's Antegren, Abbott's Humira and Protein Design Labs' HuZAF for Crohn's disease were presented at the meeting. Presentations of non-MAb's included Otsuka's OPC-6535, Alizyme's renzapride and Solvay's cilansetron.